Product Name: |
Mepivacaine HCl |
CAS: | 1722-62-9 |
MF: | C15h22n2o.Clh |
Supplier Name: | Hebei Disha Import and Export Trade Co. LTD |
Shelf Life: | 24 Months |
Package: | 1kg/foil bag(net weight 1kg, gross weight 1.2kg), 25kg/fiber drum(net weight 25kg, gross weight 28kg) According to customer needs |
Storage: | Stored in a cool and dry well closed container and in ventilated area, kept away from moisture and strong light or high temperature. |
Product Name:Mepivacaine Hydrochloride
Other Name:Mepivacaine HCL
Chemical Name:n-(2,6-dimethylphenyl)-1-methyl-2-piperidinecarboxamide hydrochloride;(1-methyl-dl-piperidine-2-carboxylicacid)-2,6-dimethylanilidehydrochloride
CAS:1722-62-9
MF:C15H22N2O.ClH
MW:282.81
EINECS:217-023-9
Assay:99% min
Appearence:White powder or white crystalline powder
Pursope:Local anesthetic drug
Package:1kg/bag;25kg/drum.
Storage:Closed and avoiding light
Usage: Anesthetic (local).
1. Mepivicaine hydrochloride is a local anesthetic of the amide type. Mepivicaine as a reasonably rapid onset and medium duration and is known by the proprietary names as Carbocaine and Polocaine. Mepivicaine is used in local infiltration and regional anesthesia. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal.
2. Half life of Mepivacaine hydrochloride, the half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates to 8.7
1. Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: pain, temperature, touch, proprioception, and skeletal muscle tone.
2. Mepivacaine hydrochloride of Absorption
Absorbed locally. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence in the anesthetic solution.
3. Rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine. The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.
4. Route of elimination.It is rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine.The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.
Series | English Name | CAS NO. | Treatment effect |
Macitentan Series | Macitentan API | 441798-33-0 | ActelionPharmaceuticalsInc( PAH) |
2-(4-Bromo-phenyl)-malonic acid dimethyl este | 149506-35-4 | ||
5-(4-Bromophenyl)-4,6-pyrimidinediol | 706811-25-8 | ||
5-(4-Bromophenyl)-4,6-pyrimidinediol | 147962-41-2 | ||
5-(4-Bromophenyl)-4,6-dichloropyrimidine;PyriMidine, 5-(4-broMophenyl)-4,6-dichloro- | 146533-41-7 | ||
Brexpiprazole Series | Brexpiprazole API | 913611-97-9 | Antidepressant |
1-benzo[b]thien-4-yl-, hydrochloride | 913614-18-3 | ||
7-Hydroxyquinolinone | 70500-72-0 | ||
1-BOC-PIPERAZINE | 57260-71-6 | ||
(2E)-N-(3-Methoxyphenyl)-3-phenyl-2-propenamide | 127033-74-3 | ||
Lurasidone Series | Lurasidone API | 367514-87-2 | Nervous system drugs |
(R,R)-1,2-bis(methanesulfonyloxymethyl) | 186204-35-3 | ||
(3aR,7aR)-4'-(1,2-Benzisothiazol-3-yl)octahydrospiro[2H-isoindole-2,1'-piperaziniuM] Methanesulfonate | 186204-37-5 | ||
(3aR,4S,7R,7aS) 4,7-Methano-1H-isoindole-1,3(2H)-dione | 14805-29-9 | ||
(1R,2R)-(-)-1,2-DICARBOXYLIC ACID | 46022-05-3 | ||
Series | 2-Amino-3-o-chlorobenzoyl-5-ethylthiophene | 50508-60-6 | Antidepressant |
2-(Aminoacetylamino)-3-(o-chlorobenzoyl)-5-ethylthiophene | 50509-09-6 | ||
Baricitinib Series | Baricitinib API | 1187594-09-7 |
Rheumatoidarthritis
(RA) |
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)-methyl)-7h-pyrrolo[2,3-d]pyrimidine | 941685-27-4 | ||
2-(1-(ethylsulfonyl)azetidin-3-ylidene) | 1187595-85-2 | ||
1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | 1029716-44-6 | ||
[4-(1H-Pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate | 1146629-77-7 | ||
1-Boc-3-(cyanomethylene)azetidine | 1153949-11-1 | ||
Apixaban Series | Apixaban API | 503612-47-3 | Thromboprophylaxis |
3-Morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydro-1H-pyridin-2-on | 545445-44-1 | ||
3-(4-Morpholinyl)-1-(4-nitrophenyl)-5,6-dihydro-2(1H)-pyridinone | 503615-03-0 | ||
4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl este | 536759-91-8 | ||
1-(4-AMinophenyl)-5,6-dihydro-3-(4-Morpholinyl)-2(1h)-pyridinone | 1267610-26-3 | ||
1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester | 503614-91-3 | ||
ethyl 6-(4-aMinophenyl)-1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate | 503615-07-4 | ||
Acetic acid, 2-chloro-2-[2-(4-methoxyphenyl)hydrazinylidene], ethyl ester | 27143-07-3 | ||
Others | Nintedanib intermediates | 2653-16-9 | IPF |
Ipragliflozin intermediates | 1034305-17-3 | Type 2 Diabetes | |
Bupropion HCL | 31677-93-7 | Antidepressant |